Management of Primary and Recurrent Clostridium difficile Infection: An Update

Background: Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections (HAI) in the United States and Canada, and incidence rates have increased worldwide in recent decades. Currently, antibiotics are the mainstay treatments for both primary and recurrent CDI, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Jocelyn, Lee, Christine H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163576/
https://www.ncbi.nlm.nih.gov/pubmed/29966323
http://dx.doi.org/10.3390/antibiotics7030054
_version_ 1783359394318123008
author Chai, Jocelyn
Lee, Christine H.
author_facet Chai, Jocelyn
Lee, Christine H.
author_sort Chai, Jocelyn
collection PubMed
description Background: Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections (HAI) in the United States and Canada, and incidence rates have increased worldwide in recent decades. Currently, antibiotics are the mainstay treatments for both primary and recurrent CDI, but their efficacy is limited, prompting further therapies to be developed. Aim: This review summarizes current and emerging therapies in CDI management including antibiotics, fecal microbiota transplantation, monoclonal antibodies, spore-based therapies, and vaccinations.
format Online
Article
Text
id pubmed-6163576
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61635762018-10-12 Management of Primary and Recurrent Clostridium difficile Infection: An Update Chai, Jocelyn Lee, Christine H. Antibiotics (Basel) Review Background: Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections (HAI) in the United States and Canada, and incidence rates have increased worldwide in recent decades. Currently, antibiotics are the mainstay treatments for both primary and recurrent CDI, but their efficacy is limited, prompting further therapies to be developed. Aim: This review summarizes current and emerging therapies in CDI management including antibiotics, fecal microbiota transplantation, monoclonal antibodies, spore-based therapies, and vaccinations. MDPI 2018-06-30 /pmc/articles/PMC6163576/ /pubmed/29966323 http://dx.doi.org/10.3390/antibiotics7030054 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chai, Jocelyn
Lee, Christine H.
Management of Primary and Recurrent Clostridium difficile Infection: An Update
title Management of Primary and Recurrent Clostridium difficile Infection: An Update
title_full Management of Primary and Recurrent Clostridium difficile Infection: An Update
title_fullStr Management of Primary and Recurrent Clostridium difficile Infection: An Update
title_full_unstemmed Management of Primary and Recurrent Clostridium difficile Infection: An Update
title_short Management of Primary and Recurrent Clostridium difficile Infection: An Update
title_sort management of primary and recurrent clostridium difficile infection: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163576/
https://www.ncbi.nlm.nih.gov/pubmed/29966323
http://dx.doi.org/10.3390/antibiotics7030054
work_keys_str_mv AT chaijocelyn managementofprimaryandrecurrentclostridiumdifficileinfectionanupdate
AT leechristineh managementofprimaryandrecurrentclostridiumdifficileinfectionanupdate

Ejemplares similares